Journal: Frontiers in Pharmacology

Article Title: Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis

doi: 10.3389/fphar.2024.1485255

Figure Lengend Snippet: FIGURE 2 Expression changes of CXCL8-CXCR1/2 in UC tissue versus normal colon tissue. (A) Multiplex fluorescent immunohistochemistry was used to measure CXCL8, CXCR1, and CXCR2 protein levels in normal colon tissue (NCT) and ulcerative colitis tissues (UCT). CXCL8 was labeled in green, CXCR1 was labeled in red, CXCR2 was labeled purple, and DAPI was used to label nuclei in blue (magnification ×200); (B–D) Changes in AOD (average optical density) protein expression levels of CXCL8-CXCR1/2 in different intestinal tissues (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 vs. NCT.

Article Snippet: The samples were then separated by SDS-PAGE, transferred to a PVDFmembrane, blocked with 5% BSA, and incubated with a primary antibody at 4°C for 14 h (CXCL8, Proteintech, diluted 1:1,000; CXCR1, Affinity, diluted 1: 1,000; CXCR2, Proteintech, diluted 1:1,000; IL-17A, BOSTER, diluted 1:1,000; NF-κB, Affinity, diluted 1:1,000; ZO-1, Affinity, diluted 1:2,000; MUC2, Abcam, diluted 1:2,000; Occludin, Affinity, diluted 1:1,000; GAPDH, Servicebio, diluted 1:4,000).

Techniques: Expressing, Multiplex Assay, Immunohistochemistry, Labeling

Journal: Frontiers in Pharmacology

Article Title: Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis

doi: 10.3389/fphar.2024.1485255

Figure Lengend Snippet: FIGURE 3 CXCL8-CXCR1/2 gene expression in the transcriptome analysis. (A) KEGG pathway enrichment reveals the UC’s top 20 significantly enriched pathways group. (B–D) GSEA results compare the UC group to the HC group, using the Normalized Enrichment Score (NES) as a key metric. NES >0 indicates core genes on the left of the peak, while NES <0 indicates core genes on the right. Significance of the Enrichment Score (ES) is assessed using the p-value.

Article Snippet: The samples were then separated by SDS-PAGE, transferred to a PVDFmembrane, blocked with 5% BSA, and incubated with a primary antibody at 4°C for 14 h (CXCL8, Proteintech, diluted 1:1,000; CXCR1, Affinity, diluted 1: 1,000; CXCR2, Proteintech, diluted 1:1,000; IL-17A, BOSTER, diluted 1:1,000; NF-κB, Affinity, diluted 1:1,000; ZO-1, Affinity, diluted 1:2,000; MUC2, Abcam, diluted 1:2,000; Occludin, Affinity, diluted 1:1,000; GAPDH, Servicebio, diluted 1:4,000).

Techniques: Gene Expression

Journal: Frontiers in Pharmacology

Article Title: Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis

doi: 10.3389/fphar.2024.1485255

Figure Lengend Snippet: FIGURE 6 Que regulated the CXCL8-CXCR1/2 axis. (A–D) CXCL8, CXCR1, and CXCR2 expression levels in mice’s colonic tissue (n = 4). (E–H) IHC expression of CXCL8, CXCR1, and CXCR2 in the colon (×100, ×400) (n = 4).*p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The samples were then separated by SDS-PAGE, transferred to a PVDFmembrane, blocked with 5% BSA, and incubated with a primary antibody at 4°C for 14 h (CXCL8, Proteintech, diluted 1:1,000; CXCR1, Affinity, diluted 1: 1,000; CXCR2, Proteintech, diluted 1:1,000; IL-17A, BOSTER, diluted 1:1,000; NF-κB, Affinity, diluted 1:1,000; ZO-1, Affinity, diluted 1:2,000; MUC2, Abcam, diluted 1:2,000; Occludin, Affinity, diluted 1:1,000; GAPDH, Servicebio, diluted 1:4,000).

Techniques: Expressing

Journal: Frontiers in Pharmacology

Article Title: Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis

doi: 10.3389/fphar.2024.1485255

Figure Lengend Snippet: FIGURE 8 Workflow for analyzing Que’s mechanisms in UC treatment. Network pharmacology, in conjunction with transcriptomic methodologies and experimental validation, demonstrated that quercetin alleviated the symptoms associated with DSS-induced colitis. It attenuates the inflammatory response, promotes the repair of colonic mucosal tissues, and elevates the levels of colonic tight junction proteins in mice with ulcerative colitis. These effects may enhance tight junction integrity and restore intestinal barrier function by modulating the IL-17A signaling pathway while simultaneously inhibiting the CXCL8-CXCR1/2 axis.

Article Snippet: The samples were then separated by SDS-PAGE, transferred to a PVDFmembrane, blocked with 5% BSA, and incubated with a primary antibody at 4°C for 14 h (CXCL8, Proteintech, diluted 1:1,000; CXCR1, Affinity, diluted 1: 1,000; CXCR2, Proteintech, diluted 1:1,000; IL-17A, BOSTER, diluted 1:1,000; NF-κB, Affinity, diluted 1:1,000; ZO-1, Affinity, diluted 1:2,000; MUC2, Abcam, diluted 1:2,000; Occludin, Affinity, diluted 1:1,000; GAPDH, Servicebio, diluted 1:4,000).

Techniques: Biomarker Discovery